Derek Archila
Stock Analyst at Wells Fargo
(3.44)
# 858
Out of 4,829 analysts
179
Total ratings
45.3%
Success rate
3.56%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $30 → $26 | $17.30 | +50.29% | 11 | May 8, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $26 → $19 | $6.61 | +187.44% | 6 | May 2, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $58 → $59 | $58.98 | +0.03% | 7 | Apr 30, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $25 | $9.50 | +163.16% | 5 | Apr 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $80 → $91 | $57.38 | +58.59% | 5 | Apr 7, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $6 → $3 | $1.19 | +152.10% | 10 | Apr 1, 2025 | |
| SEPN Septerna | Maintains: Equal-Weight | $14 → $11 | $6.69 | +64.42% | 3 | Mar 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Equal-Weight | $11 → $10 | $4.09 | +144.50% | 5 | Mar 21, 2025 | |
| QTTB Q32 Bio | Maintains: Equal-Weight | $16 → $15 | $1.55 | +867.74% | 2 | Mar 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $723 → $741 | $549.27 | +34.91% | 11 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $36.17 | -0.47% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $19.62 | +159.94% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $6 | $1.23 | +387.80% | 4 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $11.31 | +23.84% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $4.22 | +113.27% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $14.02 | +220.97% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $1.47 | +716.33% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $12.39 | +117.92% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $2.36 | +452.02% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $30.07 | +89.56% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $2.11 | +1,037.44% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $97.17 | +55.40% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.28 | +418.29% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $151.46 | +90.81% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $1.24 | +787.10% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $18.33 | +101.85% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $1.60 | +525.00% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $0.80 | +2,405.64% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.62 | +397.24% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.30 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $25.31 | +662.54% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $82.30 | -50.18% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $10.38 | +1,441.43% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.83 | +510.38% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $3.95 | +634.18% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $2.11 | +2,269.67% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $10.38 | +391.33% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $27.01 | +225.81% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $25.12 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.93 | - | 2 | Aug 3, 2017 |
Apellis Pharmaceuticals
May 8, 2025
Maintains: Equal-Weight
Price Target: $30 → $26
Current: $17.30
Upside: +50.29%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $26 → $19
Current: $6.61
Upside: +187.44%
Incyte
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $58 → $59
Current: $58.98
Upside: +0.03%
Nurix Therapeutics
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $9.50
Upside: +163.16%
Rhythm Pharmaceuticals
Apr 7, 2025
Maintains: Overweight
Price Target: $80 → $91
Current: $57.38
Upside: +58.59%
Cabaletta Bio
Apr 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.19
Upside: +152.10%
Septerna
Mar 28, 2025
Maintains: Equal-Weight
Price Target: $14 → $11
Current: $6.69
Upside: +64.42%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.09
Upside: +144.50%
Q32 Bio
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.55
Upside: +867.74%
argenx SE
Feb 28, 2025
Maintains: Overweight
Price Target: $723 → $741
Current: $549.27
Upside: +34.91%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $36.17
Upside: -0.47%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $19.62
Upside: +159.94%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $1.23
Upside: +387.80%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $11.31
Upside: +23.84%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.22
Upside: +113.27%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $14.02
Upside: +220.97%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $1.47
Upside: +716.33%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $12.39
Upside: +117.92%
Dec 11, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $2.36
Upside: +452.02%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $30.07
Upside: +89.56%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $2.11
Upside: +1,037.44%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $97.17
Upside: +55.40%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $3.28
Upside: +418.29%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $151.46
Upside: +90.81%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $1.24
Upside: +787.10%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $18.33
Upside: +101.85%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $1.60
Upside: +525.00%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $0.80
Upside: +2,405.64%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $3.62
Upside: +397.24%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.30
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $25.31
Upside: +662.54%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $82.30
Upside: -50.18%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $10.38
Upside: +1,441.43%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.83
Upside: +510.38%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $3.95
Upside: +634.18%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $2.11
Upside: +2,269.67%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $10.38
Upside: +391.33%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $27.01
Upside: +225.81%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $25.12
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $16.93
Upside: -